Home About us Events Media data Subscribe Links News Email alert Search Contact us Blog  
Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
  
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 		 
 
 

Beyond mAbs with TandAbs

With enhanced efficacy due to a bispecific mode of action and an excellent safety profile partly due to the absence of an Fc region, TandAbs represent a strong front runner in the race to develop alternatives to first-generation antibody therapeutics.

Uwe Reusch and Stefan Knackmuss at Affimed Therapeutics AG (June 2011)

    View full article    |    Back to Biopharma section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |